Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as “AML not otherwise specified” (AML-NOS) or “AML with myelodysplasia-related changes” (AML-MRC)

Miriam Miesner, Claudia Haferlach, Ulrike Bacher, Tamara Weiss, Katja Macijewski, Alexander Kohlmann, Hans-Ulrich Klein, Martin Dugas, Wolfgang Kern, Susanne Schnittger, Torsten Haferlach

Blood (2010) 116 (15): 2742–2751.

https://doi.org/10.1182/blood-2010-04-279794

Published: 2010

Includes: Supplemental data

Journal Articles

Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin ( NPM1 )

Brunangelo Falini, Katja Macijewski, Tamara Weiss, Ulrike Bacher, Susanne Schnittger, Wolfgang Kern, Alexander Kohlmann, Hans-Ulrich Klein, Marco Vignetti, Alfonso Piciocchi, Paola Fazi, Maria Paola Martelli, Antonella Vitale, Stefano Pileri, Miriam Miesner, Antonella Santucci, Claudia Haferlach, Franco Mandelli, Torsten Haferlach

Blood (2010) 115 (18): 3776–3786.

https://doi.org/10.1182/blood-2009-08-240457

Published: 2010

Includes: Supplemental data

Journal Articles

Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome–negative myeloproliferative neoplasms

Blood (2010) 115 (14): 2882–2890.

https://doi.org/10.1182/blood-2009-07-235119

Published: 2010

Includes: Supplemental data

Journal Articles

SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations

Daniel Nowak, Seishi Ogawa, Markus Müschen, Motohiro Kato, Norihiko Kawamata, Antonie Meixel, Verena Nowak, Han S. Kim, Sharon Kang, Ronald Paquette, Mi-Sook Chang, Nils H. Thoennissen, Max Mossner, Wolf-Karsten Hofmann, Alexander Kohlmann, Tamara Weiss, Torsten Haferlach, Claudia Haferlach, H. Phillip Koeffler

Blood (2010) 115 (5): 1049–1053.

https://doi.org/10.1182/blood-2009-03-210377

Published: 2010

Includes: Supplemental data

Journal Articles

14q Deletions Are Recurrent Aberrations in CLL and Other Mature B-Cell Neoplasms and Show a High Coincidence with An Unmutated IgVH Status and Trisomy 12, and Are Associated with An Intermediate Overall Survival and a Shorter Time to Treatment.

Lena Reindl, Frank Dicker, PhD, Tamara Weiss, Wolfgang Kern, MD, Susanne Schnittger, PhD, Torsten Haferlach, MD, Claudia Haferlach, MD

Blood (2009) 114 (22): 1262.

https://doi.org/10.1182/blood.V114.22.1262.1262

Published: 2009

Journal Articles

Towards a Comprehensive Prognostic Score in CLL Based On a Combination of Genetic Parameters.

Claudia Haferlach, MD, Frank Dicker, PhD, Tamara Weiss, Susanne Schnittger, PhD, Christian Beck, MD, Albert Grote-Metke, Daniel V Oruzio, Wolfgang Kern, MD, Torsten Haferlach, MD

Blood (2009) 114 (22): 1234.

https://doi.org/10.1182/blood.V114.22.1234.1234

Published: 2009

Journal Articles

Prevalence and Prognostic Impact of Allelic Imbalances Associated with Leukemic Transformation of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.

Blood (2009) 114 (22): 1280.

https://doi.org/10.1182/blood.V114.22.1280.1280

Published: 2009

Journal Articles

The Presence of Multilineage Dysplasia (MLD) Has No Significant Impact On Biological, Clinico-Pathological, and Prognostic Features in AML with Mutated Nucleophosmin ( NPM1 ).

Torsten Haferlach, MD, Katja Macijewski, Tamara Weiss, Ulrike Bacher, MD, Susanne Schnittger, PhD, Wolfgang Kern, MD, Alexander Kohlmann, PhD, Hans-Ulrich Klein, Marco Vignetti, Alfonso Piciocchi, Paola Fazi, Maria Paola Martelli, Stefano Aldo Pileri, Miriam Miesner, Antonella Santucci, Teresa Marafioti, MD, Claudia Haferlach, MD, Franco Mandelli, MD, Brunangelo Falini, MD

Blood (2009) 114 (22): 2618.

https://doi.org/10.1182/blood.V114.22.2618.2618

Published: 2009

Journal Articles

Clinical Phenotype of Myeloproliferative Neoplasms with Activating CBL -mutations Resembles Chronic Myelomonocytic Leukemia.

Juliana Popa, MD, Susanne Schnittger, PhD, Philipp Erben, MD, Tamara Weiss, Ayalew Tefferi, MD, Eva M Kanders, Eva Lengfelder, MD, Martin C. Müller, MD, Torsten Haferlach, MD, Andreas Hochhaus, MD, Wolf-Karsten Hofmann, MD, Andreas Reiter, MD

Blood (2009) 114 (22): 3895.

https://doi.org/10.1182/blood.V114.22.3895.3895

Published: 2009

Journal Articles

Next-Generation Sequencing Technology Reveals a Characteristic Pattern of Molecular Mutations in 75% of Chronic Myelomonocytic Leukemia (CMML) by Detecting Frequent Alterations in TET2 , RUNX1 , CBL , and RAS .

Alexander Kohlmann, PhD, Vera Grossmann, MA, Claudia Haferlach, MD, Beray Kazak, Sonja Schindela, Hans-Ulrich Klein, Tamara Weiss, Frank Dicker, PhD, Susanne Schnittger, PhD, Martin Dugas, MD, Wolfgang Kern, MD, Torsten Haferlach, MD

Blood (2009) 114 (22): 417.

https://doi.org/10.1182/blood.V114.22.417.417

Published: 2009

Journal Articles

AML with Multilineage Dysplasia (MLD) Correlates with MDS-Related Cytogenetic Abnormalities and a Prior History of MDS or MDS/MPN but Has No Independent Prognostic Relevance: A Comparison of 461 Cases Classified as “AML Not Otherwise specified” or “AML with Myelodysplasia-Related changes” as Defined by the 2008 WHO Classification.

Miriam Miesner, Tamara Weiss, Katja Macijewski, Ulrike Bacher, MD, Susanne Schnittger, PhD, Claudia Haferlach, MD, Wolfgang Kern, MD, Torsten Haferlach, MD

Blood (2009) 114 (22): 823.

https://doi.org/10.1182/blood.V114.22.823.823

Published: 2009

Journal Articles

Prognostic Impact of FLT3 Mutation Load in NPM1 Mutated AML.

Susanne Schnittger, PHD, Tamara Weiss, Claudia Haferlach, MD, Wolfgang Kern, MD, Torsten Haferlach, MD

Blood (2009) 114 (22): 826.

https://doi.org/10.1182/blood.V114.22.826.826

Published: 2009

Journal Articles

NPM1 Mutations Have a High Impact On the Development of Secondary AML.

Susanne Schnittger, PHD, Tamara Weiss, Frank Dicker, PHD, Jana Sundermann, Wolfgang Kern, MD, Claudia Haferlach, MD, Torsten Haferlach, MD

Blood (2009) 114 (22): 999.

https://doi.org/10.1182/blood.V114.22.999.999

Published: 2009

Journal Articles

Mutations of TET2 and JAK2 but Not CBL Are Detectable in a High Portion of Patients with Refractory Anemia with Ring Sideroblasts and Thrombocytosis (RARS-T).

Johanna Flach, Sonja Schindela, Frank Dicker, PhD, Susanne Schnittger, PhD, Alexander Kohlmann, PhD, Tamara Weiss, Wolfgang Kern, MD, Torsten Haferlach, MD, Claudia Haferlach, MD

Blood (2009) 114 (22): 1766.

https://doi.org/10.1182/blood.V114.22.1766.1766

Published: 2009

Journal Articles

AML with CBFB-MYH11 Rearrangement Is Characterized by RAS Pathway Alterations in 92% of Cases and Demonstrates a High Frequency of NF1 Deletions.

Claudia Haferlach, MD, Frank Dicker, PhD, Alexander Kohlmann, PhD, Sonja Schindela, Tamara Weiss, Wolfgang Kern, MD, Susanne Schnittger, PhD, Torsten Haferlach, MD

Blood (2009) 114 (22): 272.

https://doi.org/10.1182/blood.V114.22.272.272

Published: 2009

Journal Articles

Correlation of Cytomorphology, Immunophenotyping, and Interphase Fluorescence in Situ Hybridization (FISH) in 381 Patients with MGUS and 310 Patients with Multiple Myeloma.

Ulrike Bacher, MD, Torsten Haferlach, MD, Wolfgang Kern, MD, Tamara Weiss, Susanne Schnittger, PhD, Claudia Haferlach, MD

Blood (2009) 114 (22): 2812.

https://doi.org/10.1182/blood.V114.22.2812.2812

Published: 2009

Journal Articles

Applicability of DHPLC for Low Sensitive Residual Disease Detection in RUNX1 and CEBPA Mutated AML.

Susanne Schnittger, PhD, Frank Dicker, PhD, Christiane Eder, PhD, Jana Sundermann, Alexandra Spiel, Nicole Wendland, Tamara Weiss, Claudia Haferlach, MD, Wolfgang Kern, MD, Torsten Haferlach, MD

Blood (2009) 114 (22): 3067.

https://doi.org/10.1182/blood.V114.22.3067.3067

Published: 2009

Journal Articles

AML with Inv(3)(q21q26) or t(3;3)(q21;q26) Are Frequently Accompanied by Mutations in RUNX1 and NRAS and Show a High Incidence of NF1 Deletions: a Study On 40 Cases.

Claudia Haferlach,, Torsten Haferlach, MD, Frank Dicker, PhD, Tamara Weiss, Wolfgang Kern, MD, Susanne Schnittger, PhD

Blood (2009) 114 (22): 273.

https://doi.org/10.1182/blood.V114.22.273.273

Published: 2009

Journal Articles

Similar Patterns of Chromosome Abnormalities in CML Occur in Addition to the Philadelphia Translocation with or without Tyrosine Kinase Inhibitor Treatment.

Claudia Haferlach, MD, Ulrike Bacher, MD, Susanne Schnittger, PhD, Tamara Weiss, Wolfgang Kern, MD, Torsten Haferlach, MD

Blood (2009) 114 (22): 3270.

https://doi.org/10.1182/blood.V114.22.3270.3270

Published: 2009

Journal Articles

CDKN1B Encoding the Cyclin-Dependent Kinase Inhibitor 1B (p27) but Not ETV6 Is Located in the Minimally Deleted Region of 12p Abnormalities in Myeloid Malignancies and Its Expression Is Associated with Outcome in Acute Myeloid Leukemia (AML).

Claudia Haferlach, MD, Alexander Kohlmann, PhD, Sonja Schindela, Tamara Weiss, Wolfgang Kern, MD, Susanne Schnittger, PhD, Torsten Haferlach, MD

Blood (2009) 114 (22): 275.

https://doi.org/10.1182/blood.V114.22.275.275

Published: 2009

NARROW

Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin ( NPM1 )

Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome–negative myeloproliferative neoplasms

SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations

14q Deletions Are Recurrent Aberrations in CLL and Other Mature B-Cell Neoplasms and Show a High Coincidence with An Unmutated IgVH Status and Trisomy 12, and Are Associated with An Intermediate Overall Survival and a Shorter Time to Treatment.

Towards a Comprehensive Prognostic Score in CLL Based On a Combination of Genetic Parameters.

Prevalence and Prognostic Impact of Allelic Imbalances Associated with Leukemic Transformation of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.

The Presence of Multilineage Dysplasia (MLD) Has No Significant Impact On Biological, Clinico-Pathological, and Prognostic Features in AML with Mutated Nucleophosmin ( NPM1 ).

Clinical Phenotype of Myeloproliferative Neoplasms with Activating CBL -mutations Resembles Chronic Myelomonocytic Leukemia.

Next-Generation Sequencing Technology Reveals a Characteristic Pattern of Molecular Mutations in 75% of Chronic Myelomonocytic Leukemia (CMML) by Detecting Frequent Alterations in TET2 , RUNX1 , CBL , and RAS .

Prognostic Impact of FLT3 Mutation Load in NPM1 Mutated AML.

NPM1 Mutations Have a High Impact On the Development of Secondary AML.

Mutations of TET2 and JAK2 but Not CBL Are Detectable in a High Portion of Patients with Refractory Anemia with Ring Sideroblasts and Thrombocytosis (RARS-T).

AML with CBFB-MYH11 Rearrangement Is Characterized by RAS Pathway Alterations in 92% of Cases and Demonstrates a High Frequency of NF1 Deletions.

Correlation of Cytomorphology, Immunophenotyping, and Interphase Fluorescence in Situ Hybridization (FISH) in 381 Patients with MGUS and 310 Patients with Multiple Myeloma.

Applicability of DHPLC for Low Sensitive Residual Disease Detection in RUNX1 and CEBPA Mutated AML.

AML with Inv(3)(q21q26) or t(3;3)(q21;q26) Are Frequently Accompanied by Mutations in RUNX1 and NRAS and Show a High Incidence of NF1 Deletions: a Study On 40 Cases.

Similar Patterns of Chromosome Abnormalities in CML Occur in Addition to the Philadelphia Translocation with or without Tyrosine Kinase Inhibitor Treatment.

CDKN1B Encoding the Cyclin-Dependent Kinase Inhibitor 1B (p27) but Not ETV6 Is Located in the Minimally Deleted Region of 12p Abnormalities in Myeloid Malignancies and Its Expression Is Associated with Outcome in Acute Myeloid Leukemia (AML).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only